Expert Interview
Understanding the results from Medicinova’s SPRINT-MS Phase 2b Trial of MN-166 in Progressive MS
Ticker(s): MNOVA neurologist with knowledge of the top-line results from the SPRINT-MS trial, an in-depth knowledge of the mechanism of progressive MS, and experience treating Progressive MS. Preferably attended the presentation of results at the 7th Joint ECTRIMS* – ACTRIMS** Meeting in Paris, France.
Please describe your background treating Progressive MS.
Can you discuss at a high level the mechanisms of Progressive MS?
N-166 was previously tested as a treatment for Relapsing MS, what is the difference in mechanism and treatment between Progressive and Relapsing MS? Why could MN-166 work for one better than the other?
MN-166 showed a significant reduction in brain atrophy compared to the placebo, but disability data was not disclosed. How strongly does this reduction in brain atrophy imply a slowing in the progression of disability in trial subjects?
Based on available data, how significant of a change in disability progression and quality of life should result from this treatment?
Based on the results of the SPRINT-MS trial, how does MN-166 compare to current treatment options, especially Roche’s Ocrevus?
As a medical professional with patients with Progressive MS, how excited are you about MN-166 as a potential treatment for the disease?
MN-166 is believed to prevent the activation of glial cells and to have attenuating effects on activated glial cells. Recent research has tied glial cells to pain from MS. Would these effects on glial cells help to reduce pain associated with MS?
MN-166 is also being tested for ALS, do the neuroprotective effects of MN-166 observed in this trial carry benefit for ALS patients?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
